Skip to content
Relatix Health

Relatix Health

Radically different

  • Participate
    • Start here
  • Services
    • Tests to participate in
  • Resources
  • About
    • Our Vision – A radically different future
    • Our mission – personalised lifelong support
    • News
    • FAQ
    • Contact
    • Trust and Privacy
    • Support us
  • Log in / Sign up
Posted on June 16, 2026 by admin

EEG Biomarkers for ADHD Stimulant Treatment

Conditions: ADHD

Interventions: Drug: methylphenidate HCl; Drug: Mixed amphetamine salts extended release

Sponsors: Boston Children’s Hospital; Seattle Children’s Hospital; Tris Pharma, Inc.

Not yet recruiting
CategoriesClinicalTrials.gov TagsADHD, Biomarker, Healthcare provider, News Approved

Post navigation

Previous PostPrevious The Efficacy and Safety of Temporal Interference Stimulation in the Treatment of Post-Traumatic Stress Disorder
Next PostNext Non-Coding RNA Gene Expression in Psychiatric Disorders
Relatix Health

Relatix Health helps people understand their minds, explore relevant support and take part in research on their own terms. We connect lived experience with responsible research while protecting privacy, dignity and choice.

For researchers, clinicians and organisations, visit our sister site, Relatix Bio.

Take part

Start here Participate Tests to participate in Log in or sign up

Find support

Resources Services FAQ I need help now

Our commitments

Our Vision Our Mission Trust and Privacy

About

About us News Support us Contact

© 2026 Relatix Health. All rights reserved.